<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83431">
  <stage>Registered</stage>
  <submitdate>5/12/2008</submitdate>
  <approvaldate>6/01/2009</approvaldate>
  <actrnumber>ACTRN12609000005257</actrnumber>
  <trial_identification>
    <studytitle>Clinical trial with ivermectine for the treatment of Mansonella ozzardi infections</studytitle>
    <scientifictitle>Clinical trial with ivermectine 150 mcg/kg for microfilarial clearance and observation of side-effects in the treatment of infections with Mansonella ozzardi</scientifictitle>
    <utrn />
    <trialacronym>Mansonella Project Brazil</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Mansoneliasis caused by Mansonella ozzardi</healthcondition>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Epidemiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ivermectin is a semisynthetic product from Streptomyces avermitilis. A potent macrocyclic lactone disaccharide antiparasitic agent to prevent and treat parasite infection in animals and in human beings. The compound has activity against internal and external parasites as arthropods, insects, filaroidea, platyhelmints and protozoa. The usual dosage for human use is 150 or 200 micrograms/kg as an unique dose, per orum.
Treatment of human beings &gt; 4  and &lt;61 years old with ivermectine 150 mcg/kg. Patients will recieve one unique dose at the beginning of the treatment.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Microfilaremia clearance 30 and 180 days post ivermectin treatment</outcome>
      <timepoint>3, 30, 60 and 180 days post ivermectine treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Side-effects caused by ivermectin</outcome>
      <timepoint>3 days post ivermectine treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1-)Mansonella ozzardi parasitaemia present on hemoscopy
2-)Older than 4 years and younger than 61 years
3-)Not pregnant or breast-feeding
4-) Volunteer</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1-)Pregnant or breast-feeding women
2-)Less than 5 years old and older than 60 years</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Subjects will be examined by hemoscopy (venopuncture) for the presence of Mansonella ozzardi in their blood. These subjects are riverine inhabitants of Purus River in the municipality of Labrea, Amazonas State, an area of high prevalence of mansoneliasis. Those who agree will be enrolled in the study , will be treated with ivermectine 150 mcg/kg (as already used for the treatment of with Onchocerca volvulus infections ) in an unique dose and followed-up for 180 days</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Biochemistry blood test will be undertaken in days 0 and 3 in order to investigate hepatic, blood and renal injuries post ivermectin use</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>20/03/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rondonia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sao Paulo</primarysponsorname>
    <primarysponsoraddress>Rua Francisco Prestes , 1234
Monte Negro-Rondonia-Brazil
CEP 76.888-000</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministry Of Health - Brazilian Government</fundingname>
      <fundingaddress>Esplanada Dos Minist?rios
Bloco "G" Sala 222
DF-Bras?lia CEP 70.058-900</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Ministry Of Health - Brazilian Government</sponsorname>
      <sponsoraddress>Esplanada Dos Minist?rios
Bloco "G" Sala 222
DF-Bras?lia CEP 70.058-900</sponsoraddress>
      <sponsorcountry>Brazil</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Mansonella ozzardi infection is highly prevalent in the Amazonian riverine population  in Brazil. The Brazilian government has no drug protocol for the treatment of such disease. In order to determine the efficacy and safety of the use of ivermectine in the treatment of such disease, 50 subjects between 5-60 years old will be enrolled and treated with ivermectine 150 mcg/kg (the usual dosage for the treatment of Onchocerca volvulus infections) in an unique dose and followed-up for 180 days in order to observe microfilaremia clearance and the occurence of  side-effects post ivermectin treatment</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sao Lucas Human Ethic Comitee</ethicname>
      <ethicaddress>Rua Alexandre Guimaraes, 1930
Porto Velho-Rondonia-BrazilCEP 78.900-000</ethicaddress>
      <ethicapprovaldate>18/03/2009</ethicapprovaldate>
      <hrec>324/2008</hrec>
      <ethicsubmitdate>28/11/2008</ethicsubmitdate>
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Luis Marcelo Aranha Camargo</name>
      <address>Rua Francisco Prestes , 1234
Monte Negro-Rondonia-Brazil
CEP 76.888-000</address>
      <phone>+5569-92198714</phone>
      <fax>+5569-35302053</fax>
      <email>spider@icb5usp.med.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Luis Marcelo Aranha Camargo</name>
      <address>Rua Francisco Prestes , 1234
Monte Negro-Rondonia-Brazil
CEP 76.888-000</address>
      <phone>+5569-92198714</phone>
      <fax>+5569-35302053</fax>
      <email>spider@icb5usp.med.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Luis Marcelo Aranha Camargo</name>
      <address>Rua Francisco Prestes , 1234
Monte Negro-Rondonia-Brazil
CEP 76.888-000</address>
      <phone>+5569-92198714</phone>
      <fax>+5569-35302053</fax>
      <email>spider@icb5usp.med.br</email>
      <country>Brazil</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>